Combination Antibody Therapy Market: Global Industry Analysis and Forecast 2016 - 2022

  • To Be Published : Dec-2016 |
  • Status : Work in progress |
  • Format :

Combination antibody therapy has gained significant recognition in past two decades. It is now a preferred drug treatment for cancers such as lymphomas and solid tumors. Antibodies for modulating immune system has also achieved a significant success clinically. Combination antibody therapy are crucial strategies for treating patients suffering from hematological malignancies and solid tumors. This therapy for tumors is based on the fundamentals of cancer cell’s antigen expression. Combination antibody therapy can function through mediating changes in antigen or receptor functions or modulating the immune system or administering a drug that becomes temporarily united with the antibody, for targeting a specific antigen. According to the journal of oncology (JCO) it has been concluded that a combination of epratuzumab with rituximab was tolerable and had substantial effect in Non-Hodgkin's Lymphoma (NHL). Nonetheless, auto immune disease such as rheumatoid arthritis can be treated by combination of alpha monoclonal antibody with low dose weekly of methotrexate. Additive effect of Rituxan anti-CD20 chimeric antibody with low dose chemotherapy can be effective in B-Cell Lymphoma.

The particular nature of the combination antibody therapy has led to more targeted and specific treatment of the cancer and tumor. Hence, become an attractive treatment in recent years due to its non-chemotherapy nature, which in turn gives a safe and secure process of killing the cancer and tumor cells. Growth for combination antibody treatment market is anticipated to gain traction in near future due to the above mentioned factors. Owing to the ability of combination antibodies to specifically target tumor cells and cancer cells has been crucial for the advancement of monoclonal antibodies combination therapy so far due to that it is expected that the CAGR for combination antibody therapy market is tend to expand in near future. Combination antibody therapy market is anticipated to grow on the backdrop of increased effort for developing dual targeting of tumor antigens such as bi-specific ADC’s and novel strategies such as masked antibodies.

Requirement of safe and chemotherapy-free cancer treatments have led towards rise in demand for combination antibody therapy. Major part of the demand is expected to be under chronic lymphocytic leukemia. However, over the year significant number of antibodies and immune system modulators have been introduced in various other cancer treatments, which has shown positive effects of disease disposal. The more convenient way for drug administration has empowered the growth of these type of cancer treatments, which further offers more patient compliance. Furthermore, the rise in prevalence of cancer around the globe has been a positive sign for combination antibody therapy market that in turn is expected to underpin the growth in use of combination therapy.

Global market for Combination antibody therapy is segmented on the basis of disease, basis of drugs, route of administration and end user:

  • Segmentation by Disease
    • Cancer
    • Tumor
    • Auto-immune disorder
  • Segmentation by Drugs
    • Nivolumab and Ipilimumab
    • Trastuzumab and Pertuzumab
    • Rituximab and Apolizumab
    • Ofatumumab, and Obinutuzumab
    • Ipilimumab and Bevacizumab
    • Others
  • Segmentation by Route of administration
    • Oral
    • Parenteral
  • Segmentation by End User
    • Hospitals
    • Ambulatory Surgical Centers
    • Cancer institutions
    • Clinical research institutes

Primary revenue drivers for combination antibody therapy are an increase in number of patients seeking safe and chemotherapy free treatment. High rate of cancer in human population globally, is estimated to affect significantly in combination antibody therapy market worldwide. Other revenue drivers include life style changes and rise in adulterated food consumption by individuals. Furthermore, the combination antibody therapy market is expected to grow on the backdrop of rise in cases of skin tumors, which includes basal cell and squamous cell carcinomas and make up 12% of all skin tumors.

On the basis of region presence, Combination antibody therapy market is segmented into five key regions: North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. Currently, North America dominates the global market for Combination antibody therapy due to high adoption and diagnosis rate, followed by Europe. Rising number of cancer patients is expected to fuel the Combination antibody therapy market. Combination antibody therapy market in Asia Pacific and Middle East and Africa is expected to register high growth due to developing healthcare infrastructure and high prevalence of tumor and cancer.

Some of the major market players in Combination antibody therapy market globally include Laboratory Corporation of EMD Millipore Corporation, Thermo Fisher Scientific Inc., GeneTex Inc., Novus Biologicals, BioLegend, Inc., PDL BioPharma, Inc, Fortress Biotech., Peregrine Pharmaceuticals Inc., Cellerant Therapeutics, Inc., Aspyrian Therapeutics, Inc. The report covers exhaustive analysis on:

  • Combination antibody therapy Market Segments
  • Combination antibody therapy Market Dynamics
  • Historical Actual Market Size, 2014 - 2015
  • Combination antibody therapy Market Size & Forecast 2016 to 2022
  • Combination antibody therapy Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Combination antibody therapy Drivers and Restraints

Regional analysis includes

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Report Highlights:

  • Shifting Industry dynamics
  • In-depth market segmentation
  • Historical, current and projected industry size Recent industry trends
  • Key Competition landscape
  • Strategies of key players and product offerings
  • Potential and niche segments/regions exhibiting promising growth
  • A neutral perspective towards market performance
Back To Top